Cat. No.
MABL-3690
Application
therapeutic, Block, ELISA, FC
Isotype
Engineer antibody
Species Reactivity
Rat, Human, Rhesus Monkey, Cynomolgus Monkey
Clone No.
GBR500 (Vatelizumab, TMC-2206)
From
Recombinant Antibody
Specificity
This antibody binds an epitope in the domain I region of human α2 integrin. This epitope spans a region encompassing amino acid residues, K40, N73, Q89, Y93, R165, and N166 and optionally, other amino acid residues of the α2 integrin I domain. This antibody is also reported to cross react with cynomolgus monkey, rhesus macaque and rat α2 I domains. Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix.
Alternative Names
ITGA2; Integrin α2β1; Integrin alpha-2/beta-1; Integrin alpha-2; CD49 antigen-like family member B; Collagen receptor; Platelet membrane glycoprotein Ia; GPIa; VLA-2 subunit alpha; BHA2.1; SAR339658
UniProt
P17301
Immunogen
The parental mouse antibody was generated by immunizing BALB/c mice with human fibrosarcoma HT1080 cells. The original humanized version was generated by grafting the CDRs of murine parental antibody onto human acceptor framework regions.
Application Notes
The binding of this antibody to recombinant GST-human α2I domain fusion protein and intact α2β1 integrin was evaluated using ELISA. It was reported that this antibody bound immobilized human α2β1 integrin with a binding affinity in the nanomolar range. The reactivity of this antibody towards α2β1 integrin expressed on blood cells from different species was evaluated by flow cytometry (US7807794). In vitro, this antibody inhibits the binding of PC3 prostate cancer cells to collagen with an EC50 of 0.035 μg/ml. To study the impact of VLA-2 on extravasation in a PC3-luc metastasis model, this antibody was used to block VLA-2 before injection of tumor cells and by pre-dosing mice with a 50 mg/kg dose i.v. Bi-weekly treatment with this antibody at 5 mg/kg successfully slowed tumor growth and was as effective as bevacizumab 5 mg/kg treatment (Attinger et al., Cancer Research 2011).
Antibody First Published
Attinger et al. GBR 500, a monoclonal VLA-2 antibody inhibits tumor and metastasis growth but not extravasation in a prostate cancer animal model . Cancer Res (2011) 71 (8_Supplement): LB-294.
Note on publication
This study was done to understand the role of VLA-2 in extravasation and metastasis of prostate cancer cells using an anti-VLA-2 antibody GBR 500.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
